pillbase.ru

Arixtra

Active substance: fondaparinux

fondaparinux sodium

Centralised EU authorisationActive

Marketing holder: Viatris Healthcare Limited

Verified 2026-10-09 · EMA

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
US 28
  • Arixtra
    INJECTION, SOLUTION · FONDAPARINUX SODIUM 5 mg/.4mL
    67457-593
    Mylan Institutional LLC
  • Arixtra
    INJECTION, SOLUTION · FONDAPARINUX SODIUM 10 mg/.8mL
    67457-595
    Mylan Institutional LLC
  • Arixtra
    INJECTION, SOLUTION · FONDAPARINUX SODIUM 2.5 mg/.5mL
    67457-592
    Mylan Institutional LLC
  • Arixtra
    INJECTION, SOLUTION · FONDAPARINUX SODIUM 7.5 mg/.6mL
    67457-594
    Mylan Institutional LLC
  • FONDAPARINUX SODIUM
    INJECTION, SOLUTION · FONDAPARINUX SODIUM 5 mg/.4mL
    55150-231
    Eugia US LLC
All products in this country (28)
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208c-4846-7b62-8e4b-494e89c8d4e3,01a1208c-75eb-79df-99a4-baa2c428a91f,01a1208e-76ed-7453-8489-69e2686eb20b,01a1208e-76f2-79f3-8b63-2950a868598c,01a1208e-e0d7-797a-b598-294900e039a4;count=28 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
EMEA/H/C/000403
Registration status
Active
ATC code
B01AX05
Sources
  • product · EMA · EMEA/H/C/000403 · Verified 2026-10-09
  • registration_status · EMA · EMEA/H/C/000403 · Verified 2026-10-09
  • ingredients.0 · EMA · EMEA/H/C/000403 · Verified 2026-10-09